Mark Baldry Net Worth

The estimated Net Worth of Mark Baldry is at least $24.5 Thousand dollars as of 1 November 2023. Mark Baldry owns over 10,257 units of X4 Pharmaceuticals stock worth over $17,036 and over the last 9 years Mark sold XFOR stock worth over $7,488.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mark Baldry XFOR stock SEC Form 4 insiders trading

Mark has made over 1 trades of the X4 Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Mark sold 10,257 units of XFOR stock worth $7,488 on 1 November 2023.

The largest trade Mark's ever made was selling 10,257 units of X4 Pharmaceuticals stock on 1 November 2023 worth over $7,488. On average, Mark trades about 1,710 units every 0 days since 2015. As of 1 November 2023 Mark still owns at least 24,690 units of X4 Pharmaceuticals stock.

You can see the complete history of Mark Baldry stock trades at the bottom of the page.

What's Mark Baldry's mailing address?

Mark's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON, MA, 02134.

Insiders trading at X4 Pharmaceuticals

Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa, and Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.

What does X4 Pharmaceuticals do?

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Complete history of Mark Baldry stock trades at Amicus Therapeutics Inc, Wave Life Sciences, and X4 Pharmaceuticals

X4 Pharmaceuticals executives and stock owners

X4 Pharmaceuticals executives and other stock owners filed with the SEC include:

• Paula Ragan,
  President, Chief Executive Officer, Corporate Secretary, Director
• Adam Mostafa,
  Chief Financial Officer, Treasurer
• Dr. Paula Ragan Ph.D.,
  Founder, CEO, Pres, Sec. & Director
• Derek M. Meisner Esq., J.D.,
  Chief Legal Officer & Corp. Sec.
• Adam S. Mostafa,
  CFO, Treasurer & Assistant Sec.
• Michael Wyzga,
  Independent Chairman of the Board
• Gary Bridger,
  Independent Director
• Murray Stewart,
  Independent Director
• David McGirr,
  Independent Director
• William Aliski,
  Independent Director
• Rene Russo,
  Director
• Candice Ellis,
  Director, Corporate Communications & Investor Relations
• Alison Lawton,
  Director
• Derek Meisner,
  General Counsel
• Arthur Taveras,
  Chief Scientific Officer
• Dr. Diego Cadavid M.D.,
  Chief Medical Officer
• Carrie Melvin M.B.A.,
  Sr. VP of Devel. Operations
• Dr. Robert David Arbeit,
  Sr. VP of Clinical Devel. and Translational Research
• Ronny Mosston M.B.A.,
  Sr. VP of HR
• Dr. Mary DiBiase Ph.D.,
  Chief Operating Officer
• Keith Woods,
  Director
• Craecker Francoise De,
  Director
• Christophe Arbet Engels,
  Chief Medical Officer
• Renato Skerlj,
  Chief Scientific Officer
• Lynne E Kelley,
  Chief Medical Officer
• Diego Cadavid,
  Chief Medical Officer
• Mary Di Biase,
  Chief Operating Officer